Skip to main content
padlock icon - secure page this page is secure

Polygonatum sibiricum polysaccharides prevent LPSinduced acute lung injury by inhibiting inflammation via the TLR4/Myd88/NFκB pathway

Buy Article:

$42.00 + tax (Refund Policy)

Inflammation plays an important role in cases of acute lung injury (ALI), and the Tolllike receptor 4/nuclear factorκB (TLR4/NFκB) pathway, which can be regulated by Polygonatum sibiricum polysaccharides (PSPs), is closely related to the dynamics of lipopolysaccharide (LPS)induced inflammation. Thus, we sought to evaluate whether or not PSPs prevent LPSinduced ALI by way of inhibiting inflammation via the TLR4/NFκB pathway in rats. We established an ALI rat model by tracheal instillation of LPS, and by preinjection of PSPs into rats to examine PSPs in the ALI rat model. We found that PSPs attenuated LPSinduced lung pathological changes in ALI rats, decreased LPSinduced myeloperoxidase (MOP) activity, and elevated malondialdehyde (MDA) levels in lung tissue. However, PSPs also decreased the LPSinduced increase in the neutrophil ratio, and decreased inflammatory factor levels in bronchoalveolar lavage fluid (BALF). Moreover, PSPs decreased LPSinduced increases in inflammatory factors measured by mRNA expression, and altered the levels of expression of TLR4, medullary differentiation protein 88 (Myd88), pIKBα/IKBα and pp65/p65 proteins in lung tissue. In vitro, PSPs also reduced apoptosis induced by LPS in BEAS2B cells by suppressing inflammation through its effect of inhibiting the TLR4/NFκB pathway. In conclusion, our results suggest that PSPs may be a potential drug for effective treatment of LPSinduced ALI, due to the ability to inhibit inflammation through effects exerted on the TLR4/Myd88/NFκB pathway.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Department of Anesthesia, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

Publication date: October 1, 2020

More about this publication?
  • Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.

    All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more